Harmony Biosciences Hits Day High with 9.97% Surge in Stock Price

Harmony Biosciences Holdings, Inc. has experienced a significant uptick in its stock performance, gaining 9.97% on July 21, 2026. The stock reached an intraday high of USD 36.91, reflecting a strong day of trading for the small-cap pharmaceutical and biotechnology company. In terms of performance metrics, Harmony Biosciences has shown resilience over the past week, with a 5.83% increase compared to a slight decline of 0.46% in the S&P 500. Over the past month, the company has achieved a notable 10.7% gain, while the S&P 500 has only managed a marginal increase of 0.11%. Despite a year-to-date performance of -1.55%, which contrasts with the S&P 500's 9.7% gain, Harmony Biosciences maintains a solid long-term fundamental strength, evidenced by an average Return on Equity (ROE) of 18.24% and a net-debt-free status. The company has also demonstrated impressive growth in net sales and operating profit, with annual growth rates of 40.30% and 65.13%, respectively. With institutional holdings at 100%, Harmony Biosciences continues to be a noteworthy player in the pharmaceuticals and biotechnology sector.